(VIANEWS) - Moderna (MRNA), LyondellBasell (LYB), Syneos Health (SYNH) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Moderna (MRNA)
1202.8% sales growth and 72.43% return on equity
Moderna's sales growth this year is expected to be 2434.2% and a negative 2.5% for next year.
Year-on-year quarterly revenue growth grew by 6398.5%, now sitting on 7.02B for the twelve trailing months.
Volume
Today's last reported volume for Moderna is 59195700 which is 287.69% above its average volume of 15268600.
Moderna's sales growth for the next quarter is 1202.8%. The company's growth estimates for the ongoing quarter and the next is 1694.9% and 1681.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 72.43%.
Volatility
Moderna's last day, last week, and last month's current volatility was 21.79%, 5.83%, and 3.11%, respectively.
Moderna's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 7.10% (day), 4.70% (last week), and 5.02% (last month), respectively.
Moderna's Stock Yearly Top and Bottom Value
Moderna's stock is valued at $236.99 at 20:22 EST, way under its 52-week high of $497.49 and way higher than its 52-week low of $70.87.
Moderna's Moving Average
Moderna's value is way under its 50-day moving average of $356.46 and way under its 200-day moving average of $294.34.Previous days news about Moderna(MRNA)
- According to MarketWatch on Monday, 1 November, "Among the highlights will be results from drugmakers Pfizer Inc. and Moderna Inc. ."
- According to MarketWatch on Monday, 1 November, "The agency told Moderna late Friday that it would need more time to review the data on the risk of myocarditis after vaccination. "
- Moderna says FDA needs more time to review covid vaccine in 12-to-17-year olds. According to MarketWatch on Monday, 1 November, "The agency told Moderna late Friday that it would need more time to review the data on the risk of myocarditis after vaccination. ", "It noted that both the U.S. Centers for Disease Control and Prevention and the World Health Organization have said that myocarditis following vaccination with mRNA vaccines has been "rare and generally mild." About 1.5 million adolescents have received the Moderna vaccine and the rare condition has been showed to be an increased risk in that age group, said the release. "
- Moderna drops after FDA setback on teen covid shots. According to Bloomberg Quint on Monday, 1 November, "The Food and Drug Administration wants more time to weigh international analyses of the risks of a rare heart inflammation, myocarditis, which may not be completed before the end of the year, Moderna said in a statement on Sunday. ", "Specialist investors still see Moderna as overvalued now that the Covid-19 crisis is slowing down, Jared Holz a strategist with Oppenheimer, said in an interview. "
2. LyondellBasell (LYB)
33.4% sales growth and 59.29% return on equity
LyondellBasell Industries N.V. operates as a chemical company in the United States, Germany, Mexico, Italy, France, Japan, China, the Netherlands, and internationally.
LyondellBasell's sales growth this year is expected to be 51.5% and a negative 5.9% for next year.
Year-on-year quarterly revenue growth grew by 87.4%, now sitting on 41.28B for the twelve trailing months.
Volume
Today's last reported volume for LyondellBasell is 2415910 which is 24.19% above its average volume of 1945230.
LyondellBasell's sales growth for the next quarter is 33.4%. The company's growth estimates for the present quarter and the next is 349.6% and 100%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 59.29%.
Volatility
LyondellBasell's last day, last week, and last month's current volatility was 2.73%, 1.81%, and 1.27%, respectively.
LyondellBasell's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.20% (day), 3.09% (last week), and 2.40% (last month), respectively.
LyondellBasell's Stock Yearly Top and Bottom Value
LyondellBasell's stock is valued at $92.97 at 20:22 EST, way under its 52-week high of $118.02 and way higher than its 52-week low of $72.04.
LyondellBasell's Moving Average
LyondellBasell's value is under its 50-day moving average of $95.42 and under its 200-day moving average of $101.80.Previous days news about LyondellBasell(LYB)
- According to Bloomberg Quint on Tuesday, 2 November, "The decision makes Kenai the third U.S. refinery for sale, after Marathon rival Phillips 66 put its Alliance Refinery in Belle Chasse, Louisiana up for sale after damage caused by Hurricane Ida and as LyondellBasell Industries NV seeks to sell its Houston refinery. "
3. Syneos Health (SYNH)
23.7% sales growth and 7.56% return on equity
Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
Syneos Health's sales growth this year is expected to be 18.8% and 8% for next year.
Year-on-year quarterly revenue growth grew by 26.6%, now sitting on 4.73B for the twelve trailing months.
Volume
Today's last reported volume for Syneos Health is 673349 which is 28.08% above its average volume of 525704.
Syneos Health's sales growth for the next quarter is 23.7%. The company's growth estimates for the current quarter and the next is 12.5% and 27.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.56%.
Volatility
Syneos Health's last day, last week, and last month's current volatility was 0.39%, 1.63%, and 1.29%, respectively.
Syneos Health's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.77% (day), 2.45% (last week), and 2.36% (last month), respectively.
Syneos Health's Stock Yearly Top and Bottom Value
Syneos Health's stock is valued at $93.50 at 20:22 EST, below its 52-week high of $97.47 and way above its 52-week low of $58.31.
Syneos Health's Moving Average
Syneos Health's worth is above its 50-day moving average of $90.29 and higher than its 200-day moving average of $88.33.4. Afya (AFYA)
20.6% sales growth and 9.71% return on equity
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil.
Afya's sales growth this year is anticipated to be 30.7% and 24.9% for next year.
Year-on-year quarterly revenue growth grew by 35.8%, now sitting on 1.42B for the twelve trailing months.
Volume
Today's last reported volume for Afya is 78271 which is 30.73% below its average volume of 113009.
Afya's sales growth for the next quarter is 20.6%. The company's growth estimates for the ongoing quarter and the next is 20% and 33.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.71%.
Volatility
Afya's last day, last week, and last month's current volatility was 0.72%, 2.35%, and 2.16%, respectively.
Afya's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.88% (day), 4.80% (last week), and 4.41% (last month), respectively.
Afya's Stock Yearly Top and Bottom Value
Afya's stock is valued at $16.24 at 20:22 EST, way below its 52-week high of $28.94 and above its 52-week low of $16.12.
Afya's Moving Average
Afya's worth is way under its 50-day moving average of $19.01 and way under its 200-day moving average of $22.38.5. Global Payments (GPN)
13.7% sales growth and 3.23% return on equity
Global Payments Inc. provides payment technology and software solutions for card, electronic, check, and digital-based payments in North America, Europe, the Asia-Pacific, and Latin America.
Global Payments's sales growth this year is anticipated to be 14.6% and 10% for next year.
Year-on-year quarterly revenue growth grew by 27.8%, now sitting on 7.98B for the twelve trailing months.
Volume
Today's last reported volume for Global Payments is 3140420 which is 22.59% above its average volume of 2561590.
Global Payments's sales growth for the next quarter is 13.7%. The company's growth estimates for the present quarter and the next is 25.7% and 21.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.23%.
Volatility
Global Payments's last day, last week, and last month's current volatility was 0.56%, 2.95%, and 1.99%, respectively.
Global Payments's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.62% (day), 4.07% (last week), and 3.09% (last month), respectively.
Global Payments's Stock Yearly Top and Bottom Value
Global Payments's stock is valued at $136.75 at 20:22 EST, way under its 52-week high of $220.81 and higher than its 52-week low of $128.61.
Global Payments's Moving Average
Global Payments's value is way under its 50-day moving average of $155.21 and way below its 200-day moving average of $179.23.6. Zoetis (ZTS)
8% sales growth and 51.94% return on equity
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally.
Zoetis's sales growth this year is anticipated to be 15.1% and 8.3% for next year.
Year-on-year quarterly revenue growth grew by 25.8%, now sitting on 7.41B for the twelve trailing months.
Volume
Today's last reported volume for Zoetis is 1511430 which is 9.69% above its average volume of 1377810.
Zoetis's sales growth is a negative 0% for the current quarter and 8% for the next. The company's growth estimates for the present quarter and the next is 0.9% and 11%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 51.94%.
Volatility
Zoetis's last day, last week, and last month's current volatility was 3.14%, 1.44%, and 0.90%, respectively.
Zoetis's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.30% (day), 2.08% (last week), and 1.69% (last month), respectively.
Zoetis's Stock Yearly Top and Bottom Value
Zoetis's stock is valued at $216.73 at 20:22 EST, below its 52-week high of $218.49 and way above its 52-week low of $141.41.
Zoetis's Moving Average
Zoetis's value is above its 50-day moving average of $203.09 and way above its 200-day moving average of $192.94.7. TriNet Group (TNET)
7.1% sales growth and 40.73% return on equity
TriNet Group, Inc. provides human resources (HR) solutions for small and midsize businesses in the United States.
TriNet Group's sales growth this year is expected to be 9.2% and 2.3% for next year.
Year-on-year quarterly revenue growth grew by 17.7%, now sitting on 4.37B for the twelve trailing months.
Volume
Today's last reported volume for TriNet Group is 418475 which is 101.56% above its average volume of 207618.
TriNet Group's sales growth for the next quarter is 7.1%. The company's growth estimates for the ongoing quarter and the next is 22.7% and negative -14.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 40.73%.
Volatility
TriNet Group's last day, last week, and last month's current volatility was 0.78%, 0.85%, and 0.68%, respectively.
TriNet Group's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.56% (day), 2.43% (last week), and 2.22% (last month), respectively.
TriNet Group's Stock Yearly Top and Bottom Value
TriNet Group's stock is valued at $102.90 at 20:22 EST, below its 52-week high of $105.75 and way higher than its 52-week low of $69.43.
TriNet Group's Moving Average
TriNet Group's value is higher than its 50-day moving average of $97.90 and way higher than its 200-day moving average of $84.79.8. Pepsico (PEP)
5.6% sales growth and 59.04% return on equity
PepsiCo, Inc. operates as a food and beverage company worldwide.
Pepsico's sales growth this year is expected to be 9.4% and 4.1% for next year.
Year-on-year quarterly revenue growth grew by 20.5%, now sitting on 74.58B for the twelve trailing months.
Volume
Today's last reported volume for Pepsico is 3548420 which is 5.72% below its average volume of 3764070.
Pepsico's sales growth for the next quarter is 5.6%. The company's growth estimates for the ongoing quarter and the next is 4.2% and 6.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 59.04%.
Volatility
Pepsico's last day, last week, and last month's current volatility was 0.01%, 0.42%, and 0.62%, respectively.
Pepsico's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.74% (day), 0.99% (last week), and 1.11% (last month), respectively.
Pepsico's Stock Yearly Top and Bottom Value
Pepsico's stock is valued at $166.00 at 20:22 EST, higher than its 52-week high of $165.87.